African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2199

Full Length Research Paper

Non-adherence to statins therapy and its impact on cardiac morbidity and mortality: A metanalysis

Zelalem Gebretsadik Anebo
  • Zelalem Gebretsadik Anebo
  • Department of Pharmacology, Faculty of Pharmacy, Near East University, Nicosia, TRNC, Cyprus.
  • Google Scholar
Nurettin Abacioglu
  • Nurettin Abacioglu
  • Department of Pharmacology, Faculty of Pharmacy, Near East University, Nicosia, TRNC, Cyprus.
  • Google Scholar


  •  Received: 16 November 2018
  •  Accepted: 13 August 2019
  •  Published: 31 December 2019

References

Abramson J, Wright J (2007). "Are lipid-lowering guidelines evidence-based?". Lancet 369(9557):168-169.
Crossref

 

Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, Khanal S (2009). Low serum 25 (OH) vitamin D levels (< 32 ng/ mL) are associated with reversible myositis-myalgia in statin-treated patients. Translational Research 153(1):11-16.
Crossref

 

Allen JK, Blumenthal RS, Margolis S, Young DR, Miller ER, Kelly K (2002). Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial. American heart Journal 144(4):678-686.
Crossref

 

Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH (2007). "Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials". Journal of the American College of Cardiology 50(5):409-418.
Crossref

 

Amareneo P, Bogousslavsky J, Callahan A (2006). High-dose atorvastatin after stroke or transient ischemic attack.The New England Journal of Medicine 355(6):549-559.
Crossref

 

Bates TR, Connaughton VM, Watts GF (2009). Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert opinion on pharmacotherapy 10(18):2973-2985.
Crossref

 

Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ (2009). Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Annals of internal medicine 150(12):830-839.
Crossref

 

Bellosta S, Paoletti R, Corsini A (2004). Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23_suppl_1):50-57.
Crossref

 

Benner JS, Glynn RJ, Mogun H, Neumann PJ,Weinstein MC, Avorn J (2002). Long-term persistence in use of statin therapy in elderly patients. Jama 288(4):455-461.
Crossref

 

Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ, Sugano DS (2004). Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 22(3):13-23.
Crossref

 

Bouchard MH, Dragomir A, Blais L, Bérard A, Pilon D, Perreault S (2007). Impact of adherence to statins on coronary artery disease in primary prevention. British Journal of Clinical Pharmacology 63(6):698-708.
Crossref

 

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Skene AM (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England journal of medicine 350(15):1495-1504.
Crossref

 

Cilla DD, Gibson DM, Whitfield LR, Sedman AJ (1996). "Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening". Journal of Clinical Pharmacology 36(7):604-609.
Crossref

 

Colivicchi F, Bassi A, Santini M, Caltagirone C (2007). Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 38(10):2652-2657.
Crossref

 

Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, Brookhart MA (2009). Statin adherence and risk of accidents: a cautionary tale.Circulation 119(15):2051.
Crossref

 

Doshi JA, Zhu J, Lee B, Kimmel S, Volpp K (2009). Impact of a prescription copayment increase on lipid lowering medication adherence in veterans. Circulation 119(3):390.
Crossref

 

Dotani MI, Elnicki DM, Jain AC, Gibson CM (2000). Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. American Journal of Cardiology 86(10):1128-1130.
Crossref

 

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, AFCAPS/TexCAPS Research Group (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Jama 279(20):1615-1622.
Crossref

 

Erhardt L, Hobbs FD (2002). Public perceptions of cardiovascular risk in five European countries: the react survey. International journal of clinical practice 56(9):638-644.

 

Falvo DR (2004). Effective patient education. A guide to increased compliance. 3rd edition. Sudbury MA: Jones and Bartlett Learning.

 

Fonarow GC, Gawlinski A, Cardin S, Moughrabi S, Tillisch JI (1997). Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program. Circulation 96(8S).

 

Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J,Torgerson J, Carey K (1996). A telecommunications system for monitoring and counseling patients with hypertension: impact on medication adherence and blood pressure control. American journal of hypertension 9(4):285-292.
Crossref

 

Fuertes JN, Mislowack A, Bennett J, Paul L, Gilbert TC, Fontan G, Boylan LS (2007). The physician-patient working alliance. Patient education and counseling 66(1):29-36.
Crossref

 

Fulmer TT, Feldman PH, Kim TS, Carty B, Beers M, Molina M, Putnam M (1999). An intervention study to enhance medication compliance in community-dwelling elderly individuals. Journal of Gerontological Nursing 25(8):6-9.
Crossref

 

Furberg CD (1999). "Natural Statins and Stroke Risk". Circulation 99(2):185-188. PMID 9892578.
Crossref

 

Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA (2006).Impact of statin copayments on adherence and medical care utilization and expenditures. American Journal of Managed Care 12:11-19.

 

Goldman DP, Joyce GF, Karaca-Mandic P (2006). Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.American Journal of Managed Care 12(1):21-29.

 

Golomb BA, Evans MA (2008). Statin adverse effects. American Journal of Cardiovascular Drugs 8(6):373-418.
Crossref

 

Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Platt R (2004). Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. Jama 292(21):2585-2590.
Crossref

 

Hermans MP, Castro Cabezas M, Strandberg T, Ferrières J, Feely J, Elisaf M, Sansoy V (2010). Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Current medical research and opinion 26(2):445-454.
Crossref

 

Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid D J, Rumsfeld JS (2006). Impact of medication therapy discontinuation on mortality after myocardial infarction. Archives of internal medicine 166(17):1842-1847.
Crossref

 

Holme I, Szarek M, Cater N (2009). On behalf of the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study. European Journal of Cardiovascular Prevention and Rehabilitation 16:315-320 
Crossref

 

Hey-Hadavi J, Kuntze E, Luo D, LePetri B (2007). Atorvastatin safety in patients 75 years and older. In Neurology 68(12):31-31

 

Jackevicius C, Li P, Tu J (2008). Prevalence,predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117:1028-1036.
Crossref

 

Jones P, Kafonek S, Hunninghake D (1998).Comparative dose efficacy study of atorvastatin versus simvastatin,pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). The American journal of cardiology 81(5):582-587.
Crossref

 

Julie A, Steve S (2002). "Cholesterol drug cited in nerve study". USA Today.

 

Kalia NK, Miller LG, Nasir K, Blumenthal RS, Agrawal N, Budoff MJ (2006). Visualizing coronary calcium is associated with improvements in adherence to statin therapy. Atherosclerosis 185(2):394-399.
Crossref

 

Kane GC, Lipsky JJ (2000). Drug-grapefruit juice interactions. In Mayo Clinic Proceedings 75(9):933-942.
Crossref

 

Klein BE, Klein R, Lee KE, Grady LM (2006). Statin use and incident nuclear cataract. Jama 295(23):2752-2758.
Crossref

 

Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, Veltri EP (2003). Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. European Heart Journal 24(8):729-741.
Crossref

 

Kotseva K, Wood D, Backer GD, Bacquer DD, Pyörälä K, Keil U (2009). EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. European Journal of Cardiovascular Prevention and Rehabilitation 16(2):121-137.
Crossref

 

Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK (2008). Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 118(18):1785-1792.
Crossref

 

Law MR, Wald NJ, Rudnicka AR (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Bmj 326(7404):1423.
Crossref

 

Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V (2006). Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese medicine 1(1):4.
Crossref

 

Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS (1986). "Mevinolin, an inhibitor of cholesterol synthesis, induces

 

mRNA for low density lipoprotein receptor in livers of hamsters and rabbits".Proceedings of the National Academy of Sciences of the United States of America 83(21):8370-8374

 

Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mitchel Y (2009). Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. The American journal of cardiology 104(1):74-81.
Crossref

 

Mahler HI, Kulik JA, Tarazi RY (1999). Effects of a videotape information intervention at discharge on diet and exercise compliance after coronary bypass surgery. Journal of Cardiopulmonary Rehabilitation and Prevention 19(3):170-177.
Crossref

 

Marquez EC, Casado JM, de Andrés López M, Corés EP, López JZ, Moreno JG, Marín JF (1998). Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Atencion primaria 22(2):79-84.

 

McGovern MP, Boroujerdi MA, Taylor MW, Williams DJ, Hannaford PC, Lefevre KE, Simpson CR (2008). The effect of the UK incentive-based contract on the management of patients with coronary heart disease in primary care.Family Practice 25(1):33-39.
Crossref

 

Molloy GJ, Perkins-Porras L, Bhattacharyya MR, Strike PC, Steptoe A (2008). Practical support predicts medication adherence and attendance at cardiac rehabilitation following acute coronary syndrome.Journal of psychosomatic research 65(6):581-586.
Crossref

 

Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR, Anderson JL (2001). Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality.The American journal of cardiology 87(3):257-261.
Crossref

 

Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Schoenhagen P (2006). Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Jama 295(13):1556-1565.
Crossref

 

Osterberg L, Blaschke T (2005). Adherence to medication. New England journal of medicine 353(5):487-497.
Crossref

 

Pan W, Pintar T, Anton J, Lee VV, Vaughn W, K Collard CD (2004). Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 110(11_suppl_1):II-45.
Crossref

 

Peterson AM, McGhan WF (2001). A decision analysis model for enhancing medication adherence in patients taking statins. Value Health 4:500.
Crossref

 

Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Goldman L (2009). Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Annals of internal medicine 150(4):243-254.
Crossref

 

Ruisinger JF, Backes JM, Gibson CA, Moriarty, PM (2009). Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. The American journal of cardiology, 103(3):393-394.
Crossref

 

Ryan O (2015). HMG-CoA Reductase Inhibitors ("Statins"): Clinical Pearls for Washington Rx Therapeutic Interchange Program (TIP).

 

Schachter M (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental and Clinical Pharmacology 19(1):117-125.
Crossref

 

Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN, Langendorfer A (1992).Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 85(4):1293-1303.
Crossref

 

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S TNT (2008).Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Journal of the American College of Cardiology 51(15):1448-1454.
Crossref

 

Silva MA, Swanson AC, Gandhi PJ, Tataronis GR (2006).Statin-related adverse events: a meta-analysis. Clinical therapeutics 28(1):26-35.
Crossref

 

Sprafka JM, Burke GL, Folsom AR, Hahn LP (1989). Hypercholesterolemia prevalence awareness, and treatment in blacks and whites: the Minnesota Heart Survey. Preventive medicine 18(4):423-432.
Crossref

 

Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Gimpelewicz CR (2008). Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. The American journal of cardiology 101(4):490-496.
Crossref

 

Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J (2004).Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Annals of Behavioral Medicine, 27(2):117-124.
Crossref

 

Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).The Lancet 344(8934):1383-1389.
Crossref

 

Sung JC, Nichol MB, Venturini F, Bailey KL, McCombs JS, Cody M (1998). Factors affecting patient compliance with antihyperlipidemic medications in an HMO population.American Journal of Managed Care 4(10):1421-1430.

 

Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA (2006).Impact of statin copayments on adherence and medical care utilization and expenditures. American Journal of Managed Care 12:11-19.

 

Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 339(19):1349-1357.
Crossref

 

Thiebaud P, Patel BV, Nichol MB, Berenbeim DM (2005). The effect of switching on compliance and persistence: the case of statin treatment. American Journal of Managed Care 11:670-674.

 

Thomas HD, Maynard C, Wagner GS, Eisenstein EL (2003).Results from a practice-based lipid clinic model in achieving low density lipoprotein cholesterol goals. North Carolina medical journal 64(6):263-266.

 

Vinker S, Shani M, Baevsky T, Elhayany A (2008). Adherence with statins over 8 years in a usual care setting. The American journal of managed care 14(6):388-392.

 

Weng HC (2008).Does the physician's emotional intelligence matter?: Impacts of the physician's emotional intelligence on the trust, patient-physician relationship, and satisfaction. Health care management review 33(4):280-288.
Crossref

 

West of Scotland Coronary Prevention Study Group.(1997).Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. European Heart Journal 18(11):1718- 1724.
Crossref

 

Wilson IB, Schoen C, Neuman P, Strollo MK, Rogers WH, Chang H, Safran DG (2007). Physician-patient communication about prescription medication nonadherence: a 50-state study of America's seniors. Journal of general internal medicine 22(1):6-12.
Crossref

 

Wilson PW, D'Agostino RB, Levy D, Belanger A M, Silbershatz H, Kannel WB (1998).Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837-1847.
Crossref

 

Winland-Brown JE, Valiante J (2000). Effectiveness of different medication management approaches on elders' medication adherence. Outcomes management for nursing practice 4(4):172-176.

 

Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007). Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC medicine 5(1):20.
Crossref

 

World Health Organisation (WHO), (2009). Mortality and Health Status. 

View

 

Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM, Scott RS (2007). Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia.The American journal of cardiology 100(9):1400-1403.
Crossref